Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 30 01 2019
accepted: 10 09 2019
entrez: 1 10 2019
pubmed: 1 10 2019
medline: 13 3 2020
Statut: epublish

Résumé

To confirm that neoplastic monocyte-derived collagen- and fibronectin-producing fibrocytes induce bone marrow (BM) fibrosis in primary myelofibrosis (PMF), we injected PMF BM-derived fibrocyte-precursor CD14+/CD34- monocytes into the tail vein of NOD-SCID-γ (NSG) mice. PMF BM-derived CD14+/CD34- monocytes engrafted and induced a PMF-like phenotype with splenomegaly, myeloid hyperplasia with clusters of atypical megakaryocytes, persistence of the JAK2V617F mutation, and BM and spleen fibrosis. As control we used normal human BM-derived CD14+/CD34- monocytes. These monocytes also engrafted and gave rise to normal megakaryocytes that, like PMF CD14+/CD34--derived megakaryocytes, expressed HLA-ABC and human CD42b antigens. Using 2 clonogenic assays we confirmed that PMF and normal BM-derived CD14+/CD34- monocytes give rise to megakaryocyte colony-forming cells, suggesting that a subpopulation BM monocytes harbors megakaryocyte progenitor capacity. Taken together, our data suggest that PMF monocytes induce myelofibrosis-like phenotype in immunodeficient mice and that PMF and normal BM-derived CD14+/CD34- monocytes give rise to megakaryocyte progenitor cells.

Identifiants

pubmed: 31569199
doi: 10.1371/journal.pone.0222912
pii: PONE-D-19-02820
pmc: PMC6768666
doi:

Substances chimiques

Antigens, CD34 0
Cd14 protein, mouse 0
HLA Antigens 0
Lipopolysaccharide Receptors 0
Jak2 protein, mouse EC 2.7.10.2
Janus Kinase 2 EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0222912

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207204
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Calcif Tissue Int. 2005 Mar;76(3):222-30
pubmed: 15692727
Blood. 2014 May 29;123(22):e123-33
pubmed: 24740812
Mol Med. 1994 Nov;1(1):71-81
pubmed: 8790603
Ann Hematol. 2006 Apr;85(4):226-32
pubmed: 16421727
J Exp Med. 2016 Aug 22;213(9):1723-40
pubmed: 27481130
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):25-36
pubmed: 30580568
Blood. 2015 Apr 23;125(17):2605-13
pubmed: 25762175
F1000Res. 2017 May 26;6:748
pubmed: 28663787
Nat Rev Immunol. 2011 Jun;11(6):427-35
pubmed: 21597472
Ann Intern Med. 1980 Jun;92(6):857-8
pubmed: 7387029
Haematologica. 2005 Aug;90(8):1128-32
pubmed: 16079113
Blood. 2005 May 1;105(9):3493-501
pubmed: 15665119
Cytometry. 2000 Dec 1;41(4):308-15
pubmed: 11084616
Cell Immunol. 1994 Jun;156(1):191-211
pubmed: 8200035
Br J Haematol. 2012 May;157(4):413-25
pubmed: 22463701
Scand J Immunol. 1996 Aug;44(2):143-9
pubmed: 8711427
Invest New Drugs. 2011 Oct;29(5):818-26
pubmed: 20372971
Blood. 2008 Feb 15;111(4):1862-5
pubmed: 18029552
Blood Rev. 2014 Jan;28(1):31-40
pubmed: 24476957
Blood. 2001 Apr 1;97(7):2023-30
pubmed: 11264167
PLoS One. 2011;6(10):e25595
pubmed: 22022418

Auteurs

Taghi Manshouri (T)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Srdan Verstovsek (S)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

David M Harris (DM)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Ivo Veletic (I)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Xiaorui Zhang (X)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Sean M Post (SM)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Carlos E Bueso-Ramos (CE)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Zeev Estrov (Z)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH